Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Fig. 3

Treatment-dependent difference in degradation biomarker profiles of patients assigned as ACR50 responders (black bars) and ACR50 non-responders (grey bars) from baseline to week 8 and predictive profiles at week 24. Figures represent serum levels of C1M (a) (TCZ n = 115; MTX n = 128), C2M (b) (TCZ n = 109; MTX n = 122), C3M (c) (TCZ n = 141; MTX n = 145) and C4M (d) (TCZ n = 140; MTX n = 146) in response to TCZ and MTX at week 8 and predictive profiles at week 24. Data are shown as mean with SEMs

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us